论文信息 - Frontline Treatment with Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX Is Extremely Potent and Safe in Patients (age ≤ 65 years) with Mantle Cell Lymphoma (MCL) - Results of Phase-II Window-1 Clinical Trial - 字舞流文

Frontline Treatment with Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX Is Extremely Potent and Safe in Patients (age ≤ 65 years) with Mantle Cell Lymphoma (MCL) - Results of Phase-II Window-1 Clinical Trial

Michael L. Wang | Shaojun Zhang | Linghua Wang | K. Patel | P. Jain | R. Kanagal-Shamanna | Changying Jiang | K. Nomie | Liang Zhang | L. Fayad | J. Westin | S. Neelapu | S. Thirumurthi | H. Lee | F. Hagemeister | G. Tang | G. N. Nogueras Gonzalez | C. Yin | J. Romaguera | F. Samaniego | L. Nastoupil | N. Fowler | N. Wagner-Bartak | C. Ok | Dayoung Jung | M. Badillo | Yixin Yao | Shuangtao Zhao | Guofan Xu | Wendy Chen | O. Oriabure | D. Santos | Omar Moghrabi | Michelle Avellaneda | L. Navsaria | Annabelle Uy | A. Pedersen | Feng Lei